Types of Immunotherapy, Mechanism of Action and Side Effects
- 12 June 2024
- book chapter
- Published by Nobel Tip Kitabevleri
- p. 11-24
Abstract
Immunotherapy has emerged as a ground breaking approach in the treatment of various cancers and autoimmune diseases, utilizing the body’s immune system to combat disease. This article reviews the mechanisms of action of different types of immunotherapy, including checkpoint inhibitors, monoclonal antibodies, and adaptive cell transfer. Checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 blockers enhance immune responses by releasing brakes on T cells, thereby promoting anti-tumor immunity. Monoclonal antibodies target specific antigens on cancer cells or immune cells, facilitating targeted destruction. Adaptive cell transfer involves modifying and re-infusing patient-derived immune cells to enhance their tumor-fighting capabilities. Despite their promise, immunotherapies can elicit immune-related adverse events ranging from mild to severe, affecting various organ systems. Common side effects include fatigue, rash, and gastrointestinal disturbances, while severe reactions may involve pneumonitis, colitis, or endocrinopathies. Understanding these mechanisms and side effects is crucial for optimizing patient care and expanding the therapeutic potential of immunotherapy.Keywords
This publication has 37 references indexed in Scilit:
- Overview of tumor immunotherapy based on approved drugsLife Sciences, 2024
- Oncolytic virus preclinical toxicology studiesJournal of Applied Toxicology, 2022
- A novel multimeric sCD19‐streptavidin fusion protein for functional detection and selective expansion of CD19‐targeted CAR‐T cellsCancer Medicine, 2022
- Tumour vasculature: Friend or foe of oncolytic viruses?Cytokine & Growth Factor Reviews, 2020
- Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptorSeminars in Immunology, 2019
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor ActivityCell Stem Cell, 2018
- Ipilimumab-induced colitis: A new challenge for gastroenterologistsGastroenterología y Hepatología (English Edition), 2016
- Monoclonal antibody-based therapies in cancer: Advances and challengesPharmacology & Therapeutics, 2013
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironmentCurrent Opinion in Immunology, 2013